Avandia to be withdrawn from market

Published: 2010-09-29 07:00:00
Updated: 2010-09-29 07:00:00
GlaxoSmithKline’s blockbuster anti-diabetic agent Avandia (rosiglitazone) will be banned from sales in the Korean market due to its possible cardiovascular risks.

The Korea Food and Drug Administration said on September 24 it has ordered the Health Insurance Review and Assessment Service to en...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.